Functional imaging to monitor vascular and metabolic response in canine head and neck tumors during fractionated radiotherapy

Acta Oncologica

Volumn 52, Issue 7, 2013, Pages 1293-1299

  Rodal, Jan ^a   Rusten, Espen ^a,b   Sovik, Åste ^c   Skogmo, Hege Kippenes ^c   Malinen, Eirik ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOHEXOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CANCER RADIOTHERAPY; CONE BEAM COMPUTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DOG; HEAD AND NECK TUMOR; INTENSITY MODULATED RADIATION THERAPY; METABOLISM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCED CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; HEAD AND NECK ADENOCARCINOMA; HEAD AND NECK CARCINOMA; HEAD AND NECK PLASMA CELL TUMOR; HISTOPATHOLOGY; IMAGE ANALYSIS; IMAGE QUALITY; IMAGING SOFTWARE; LINEAR ACCELERATOR; METABOLIC PARAMETERS; PET-CT SCANNER; PLASMACYTOMA; RADIATION DOSE FRACTIONATION; RADIOLOGICAL PARAMETERS; TREATMENT DURATION; TUMOR VASCULARIZATION;

ANIMALS; CONE-BEAM COMPUTED TOMOGRAPHY; DOG DISEASES; DOGS; DOSE FRACTIONATION; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84884562316     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.812800     Document Type: Article

References (24)

1. Eisenhauer E A, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247
2. Wahl R L, Jacene H, Kasamon Y, Lodge M A. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(SUPPL. 1):122S-50S.
3. Miles K A. Tumour angiogenesis anDits relation to contrast enhancement on computed tomography: A review. Eur J Radiol 1999;30:198-205
4. Brix G, Griebel J, Kiessling F, Wenz F. T racer kinetic modelling of tumour angiogenesis based on dynamic contrastenhanced CT and MRImeasurements. Eur J Nucl Med MoLimaging 2010;37(SUPPL. 1):S30-51
5. Zhu A, Marcus DM, Shu HK, Shim H. A pplication of metabolic PET imaging in radiation oncology. Radiat Res 2012;177:436-48
6. Hatt M, van Stiphout R, le Pogam A, Lammering G, Visvikis D, Lambin P. Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PET. Acta Oncol 2013;52:619-26
7. Mayr NA, Yuh WT, Jajoura D, Wang JZ, Lo SS, Montebello JF, et al. Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer. Cancer 2010;116:903-12
8. Rusten E, Rodal J, Revheim ME, Skretting A, Bruland OS, Malinen E. Quantitative dynamic (18)FDG-PET and tracer kinetic analysis of soft tissue sarcomas. Acta OncoLepub 2012 Dec 3
9. Malinen E, Rodal J, Knudtsen IS, Sovik A, Skogmo H.K. Spatiotemporal analysis of tumor uptake patterns in dynamic (18)FDG-PET and dynamic contrast enhanced CT. Acta Oncol 2011;50:873-82
10. Roe K, Aleksandersen T B, Kristian A, Nilsen LB, Seierstad T, Qu H, et al. Preclinical dynamic 18F-FDG PET-tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncol 2010;49:914-21
11. Mullani NA, Herbst RS, O 'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor blood flow measured by PET dynamic imaging of fi rst-pass 18F-FDGuptake: A comparison with 15O-labeled water-measured blood flow. J Nucl Med 2008;49:517-23
12. Revheim M E, Kristian A, Malinen E, Bruland OS, Berner JM, Holm R, et al. Intermittent and continuous imatinib in a humaNgIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol 2013;52:776-82
13. Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, et al. Evaluation of breast tumor blood flow with dynamic fi rst-pass 18F-FDG PET/ CT: Comparison witHangiogenesis markers and prognostic factors. J Nucl Med 2012;53:512-20
14. Vriens D, De Geus-Oei L F, Heerschap A, van Laarhoven H W, Oyen WJ. Vascular and metabolic response to bevacizumabcontaining regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and dynamic 18F-FDG-PET. Clin Colorectal Cancer 2011;10:E1-5
15. Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, et al. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: Value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res 2011;17:2400-9
16. Fuss M. S trategies of assessing and quantifying radiation treatment metabolic tumor response using F18 FDG Positron Emission Tomography (PET). Acta Oncol 2010;49:948-55
17. Sovik A, Rodal J, Skogmo H.K, Lervag C, Eilertsen K, Malinen E. Adaptive radiotherapy based on contrast enhanced cone beam CT imaging. Acta Oncol 2010;49:972-7
18. Rodal J, Sovik S, SkogmOh K, Knudtsen I S, Malinen E. Feasibility of contrast-enhanced cone-beam CT for target localization and treatment monitoring. Radiother Oncol 2010;97:521-4
19. Miles KA, Williams RE. W arburg revisited: Imaging tumour blood flow and metabolism. Cancer Imaging 2008;8:81-6
20. Goh V, Shastry M, Engledow A, Kozarski R, Peck J, Endozo R, et al. Integrated (18)F-FDG PET/CT and perfusion CT of primary colorectal cancer: Effect of inter-anDintraobserver agreement on metabolic-vascular parameters. AJR Am J Roentgenol 2012;199:1003-9
21. Eby P R, Partridge S C, White S W, Doot R K, Dunnwald L K, Schubert EK, et al. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol 2008;15:1246-54
22. Igaki H, Nakagawa K, Yamashita H, Terahara A, Haga A, Shiraishi K, et al. Contrast media-assisted visualization of brain metastases by kilovoltage cone-beam CT. Acta Oncol 2009;48:314-7
23. Andersen E K, Hole K H, Lund K V, Sundfor K, Kristensen GB, Lyng H, et al. Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome. Radiother Oncol 2013;107:117-22
24. Caruso R, Parisi A, Bonanno A, Paparo D, Quattrocchi E, Branca G, et al. Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: A brief review. Oncol Lett 2012;3:16-8